

PROTECT Presentations

List of abstracts submitted for presentations at the International Conference for Pharmacoepidemiology (ICPE), Taipei, Taiwan, 24-27 October 2014.

	Title	Lead Author	Authors	WP	Status
1	A regulators' challenge: the transfer of new scientific knowledge into regulatory practice. The example of PROTECT.	EMA	Kurz X., Arlett P.	WP1	Accepted as poster
2	ENCePP-HTA Working Group 2014 survey of members experience in conducting research to support HTA	EMA	Kevin Blake, Massoud Toussi, Xavier Kurz, Yvonne Lis, Vera Ehrenstein, Nawab Qizilbash and Nicholas Moore	WP1	Accepted as poster
3	Challenges in implementing findings of regulatory science to evaluate and improve the drug regulatory system	UU	Marie L De Bruin, Xavier Kurz, Jacqueline Bouvy, David Martin, Jarno Hoekman, K. Arnold Chan, Andrew Roddam, Robert Reynolds, Gerald Dal Pan, Hans Ebbers, Bert Leufkens		Symposium (accepted)
4	Instrumental Variables Analysis Using Multiple Databases: an Example of Antidepressants Use and Risk of Hip Fracture.	UU	MJ Uddin, RHH Groenwold, A de Boer, H Gardarsdottir, E. Martin, G. Candore, SV Belitser, AW Hoes, KCB Roes, OH Klungel	WP2 (WG2)	Accepted as oral presentation
5	Evaluating Different Preference Based Instrumental Variables in Two Primary Care Databases: a Study of Beta2-Agonist Use and Risk of Myocardial Infarction.	UU	MJ Uddin, RHH Groenwold, A de Boer, A Afonso, P Primatesta, C Becker, SV Belitser, AW Hoes, KCB Roes, OH Klungel	WP2 (WG2)	Accepted as oral presentation
6	The Use of Prior Event Rate Ratio Adjustment Method for Controlling Unmeasured Confounding in Pharmacoepidemiologic Studies: A Cautionary Note.	UU	MJ Uddin, RHH Groenwold, TP van Staa, A de Boer, SV Belitser, AW Hoes, KCB Roes, OH Klungel	WP2	Accepted as oral presentation
7	Association between inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction: a methodological comparison of two databases.	UU	Afonso A.*, Schmiedl S.*, Becker C, Primatesta P, Plana E, Souverein P, Korevaar J.C, Hasford J, Reynolds R, de Groot M.C.H, Schlienger R, Klungel O, Rottenkolber M	WP2 (WG1)	Accepted as poster
8	Risk of hip fractures associated with benzodiazepines: common methodology but different results in a multi-site cohort study. The PROTECT project.	AEMPS	G Requena, C Huerta, H Gardarsdottir, M Miret, E Martín, PC Souverein, C Schneider, R González-González, A Bate, Y Alvarez, A Alvarez, D Montero, LA Garcia-Rodríguez, R Reynolds, R Schlienger, MCH de Groot, OH Klungel and F de Abajo	WP2 (WG1)	Accepted as poster

Title	Lead Author	Authors	WP	Status
9 Understanding inconsistent results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip fracture.	UU	H Gardarsdottir, V Abbing-Karahagopian, P Souverein, E Martin, C Huerta, F de Abajo, H Leufkens, G Candore, Y Alvarez, J Slattery, M Miret, G Requena, M Gil, R Groenwold, R Reynolds, R Schlienger, M de Groot, OH Klungel, T van Staa, T Egberts, ML De Bruin	WP2	Accepted as oral presentation
10 Impact of varying control moment selection in a case-crossover (CCO) study on antidepressant drug (AD) use and hip/femur fracture (HFF) in PROTECT.	UU	Mark C.H. De Groot, Svetlana V. Belitser, Patrick C. Souverein, Helga Gardarsdottir, Rolf H.H. Groenwold, Gianmario Candore, Yolanda Alvarez, Raymond G. Schlienger, Robert Reynolds, Olaf H. Klungel	WP2 (WG1)	Accepted as poster
11 No impact of adjusting for lifestyle factors or general practice on risk estimates for the association between antidepressants and hip/femur fracture.	UU	P.C. Souverein, M.C.H. de Groot, E. Martin, C. Huerta, G. Candore, Y. Alvarez, J. Slattery, J. Logie, G. Requena, M. Gil, F. de Abajo, R. Reynolds, R.G. Schlienger, O.H. Klungel and H. Gardarsdottir	WP2 (WG1)	Accepted as poster
12 Do case-only designs yield consistent results between them and across different databases (DBs)? Hip fractures associated with benzodiazepines (BZD) as a case study.	AEMPS	G Requena, J Logie, E Martín, C Huerta, R González-González, N Boudiaf, A Alvarez, A Bate, LA Garcia-Rodríguez, R Reynolds, R Schlienger, M de Groot, OH Klungel, F de Abajo and I Douglas	WP2 (WG1)	Accepted as poster
13 Risk of hip fractures associated with benzodiazepines: applying common protocol to a multi-database nested case-control study. The PROTECT project.	AEMPS	G Requena, John Logie, R González-González, H Gardarsdottir, A Afonso, PC Souverein, E Martín, N Boudiaf, C Huerta, A Bate, Y Alvarez, M Gil, LA Garcia-Rodríguez, R Reynolds, R Schlienger, MCH de Groot, OH Klungel and F de Abajo	WP2 (WG1)	Accepted as poster
14 Impact of methodological choices on findings from pharmacoepidemiological studies: final results of the IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) project.	UU	O.H.Klungel, M.C.H. de Groot, H. Gardarsdottir, R. Brauer, L. Grimaldi-Bensouda, C. Gasse, X. Kurz, R. Reynolds.	WP2+WP6	Symposium (accepted)
15 Calcium channel blockers and cancer risk using the UK CPRD.	Laser	Grimaldi-Bensouda L, de Groot M.H.C., Hesse U, Reynolds R, Klungel O, Rossignol M.	WP2 (WG1)	Accepted as oral presentation
16 The risk of acute liver injury among users of antibiotic medications: The results of a nested case-control study using European outpatient	Amgen-LSTHM	Ruth Brauer, Ian Douglas, Luis Alberto Garcia Rodriguez, Andrew Bate, Liam Smeeth, Robert	WP2 (WG1)	Accepted as poster

Title	Lead Author	Authors	WP	Status
healthcare data.		Reynolds, Olaf Klungel and Ana Ruigómez		
17 Antidepressant Use and the Risk of Hip Fracture: a Comparison of Marginal Structural Models and Conventional Regression Methods.	UU	M. Sanni Ali, R.H.H. Groenwold, S.V. Belitser, P.C. Souverein, H. Gardarsdottir, A.W. Hoes, A. de Boer, Olaf H. Klungel	WP2 (WG2)	Accepted as oral presentation
18 Antidepressant Use and the Risk of Hip Fracture: a self-controlled case series approach in two primary care databases	UU	M.Sanni Ali, Mark C.H. de Groot, Giammario Candore, Rolf HH Groenwold, Patrick C Souverein, Yolanda Alvarez, Md. J Uddin, Arno W Hoes, A de Boer, Olaf H Klungel and Helga Gardarsdottir.	WP2 (WG1)	Accepted as poster
19 Propensity Score Matching and Unmeasured Covariate Imbalance: a simulation study.	UU	M. Sanni Ali, R.H.H. Groenwold, S.V. Belitser, A.W. Hoes, A. de Boer, O.H. Klungel	WP2 (WG2)	Accepted as oral presentation
20 Advanced Topics in Pharmacoepidemiology - Benefit-Risk Assessment, Communication and Evaluation throughout the Life Cycle of Therapeutic Products: PROTECT Benefit-Risk Group	Sanofi	Juhaeri J.	WP5	Accepted as oral presentation
21 Impact of subgroup analyses and adjustment by stratification on safety signal detection for individual case reports.	MHRA	Seabroke S, Juhlin K, Candore G, Wisniewski A, Quarcoo N, Painter JL, Soeria-Atmadja D, Tregunno P, Norén GN, Slattery J.	WP3	Accepted as poster
22 Structured assessment for prospective identification of potential safety signals in electronic health records.	NU	Cederholm S, Asiiimwe A, Bate A, Bhayat F, Brobert G, Hill G, Star K, Norén GN.	WP3	Accepted as poster
23 Evaluation of statistical measures for adverse drug interaction surveillance.	WHO-UMC	Juhlin K, Soeria-Atmadja D, Thakrar B, Norén GN.	WP3	Accepted as poster